CuriosityStream Announces Third Quarter 2020 Financial Results

CuriosityStream Announces Third Quarter 2020 Financial Results

  • Third quarter 2020 revenue of $8.7 million, up 83% year-over-year
  • Gross margin increases to 61% year-over-year from 59% in Q3 2019
  • Strengthens executive team with key industry veterans  

SILVER SPRING, Md.–(BUSINESS WIRE)–
CuriosityStream Inc. (NASDAQ: CURI), a global factual entertainment company, today announced its financial results for the third quarter ending September 30, 2020.

“We had a strong third quarter, with an 83% year-over-year increase in revenue and growth across all lines of business. Our subscribers more than doubled year over year, with notable increases in annual plans and international subscriptions, as we continued to offer fresh and unique original content every week,” said Clint Stinchcomb, President & CEO. “We continue to be on a three-year trajectory of doubling annual revenue with large recurring revenues and high gross margins as we drive growth across the entire business.”

Third Quarter 2020 Financial Results

  • Revenue of $8.7 million, up from $4.8 million in the third quarter of 2019;
  • Total paying subscribers of approximately 13 million, up 108% year-over-year;
  • Gross margin increased 200 basis points year-over-year to 61%;
  • Operating loss was $(6.8) million compared to operating loss of $(10.1) million in the third quarter of 2019;
  • EBITDA was $(6.7) million compared to EBITDA of $(10.0) million in the third quarter of 2019;
  • GAAP net loss was $(6.7) million and GAAP basic and diluted net loss per share was $(0.56);
  • Sources of cash totaled $23.3 million as of September 30, 2020.

Business Highlights

  • Closed business combination with Software Acquisition Group, Inc. (NASDAQ: SAQN) and began trading on the NASDAQ exchange under ticker symbol “CURI” on October 15, 2020, becoming the first streaming media company devoted to factual entertainment to go public;
  • Named international media executive Bakori Davis to the newly created position of Managing Director and Head of International Distribution;
  • Named industry veteran Nate Stamos VP of Brand Partnerships;
  • Appointed entertainment and cable industry pioneer Matthew Blank, former Chairman and CEO of Showtime Networks, Inc., to CuriosityStream’s Board of Directors;
  • Announced several brand-defining original series including MY WILD BACKYARD,the third season of 4th AND FOREVER, DOUG TO THE RESCUE and NATURE THROUGH HER EYES;
  • In a separate release today, CuriosityStream announced the November 19th, 2020 world premiere of the original new series BEYOND THE SPOTLIGHT from Executive Producer Leonardo DiCaprio and Appian Way Productions and Stephen David Entertainment. First episodes feature Shaquille O’Neal, Kristen Bell and Samuel L. Jackson and LaTanya Richardson Jackson.

Financial Outlook

For the fourth quarter of 2020, CuriosityStream currently expects the following:

  • Revenue of at least $11.3 million, or 69% year-over-year growth

For the full year 2020 & 2021, CuriosityStream currently expects the following:

  • 2020 revenue of at least $39.5 million, or 119% year-over-year growth
  • 2021 revenue of at least $71 million, or 80% year-over-year growth

Conference Call Information

CuriosityStream will host a Q&A conference call today to discuss the Company’s Q3 2020 results at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast of the call will be available on the CuriosityStream Investor Relations website at https://investors.curiositystream.com. A live dial-in is available domestically at (800) 585-8367 or internationally at (416) 621-4642, with passcode 9085595.

An audio replay of the conference call will be available for two weeks following the call and available on the CuriosityStream Investor Relations website at https://investors.curiositystream.com.

Forward-Looking Statements

Certain statements in this press release may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, CuriosityStream’s expectations or predictions of future financial or business performance or conditions and the information under the heading “Financial Outlook” in this press release. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates,” “predicts” or “intends” or similar expressions. Such forward-looking statements involve risks and uncertainties that may cause actual events, results or performance to differ materially from those indicated by such statements. Certain of these risks are identified and discussed under “Risk Factors” in the Definitive Proxy Statement on Schedule 14A filed on September 22, 2020, and in CuriosityStream’s other SEC filings. These risk factors will be important to consider in determining future results and should be reviewed in their entirety. Forward-looking statements are based on the current belief of the management of CuriosityStream, based on currently available information, as to the outcome and timing of future events, and involve factors, risks, and uncertainties that may cause actual results in future periods to differ materially from such statements. However, there can be no assurance that the events, results or trends identified in these forward-looking statements will occur or be achieved. Forward-looking statements speak only as of the date they are made, and CuriosityStream is not under any obligation, and expressly disclaims any obligation to update, alter or otherwise revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Readers should carefully review the statements set forth in the reports that CuriosityStream has filed or will file from time to time with the SEC.

In addition to factors previously disclosed in CuriosityStream’s reports filed with the SEC and those identified elsewhere in this communication, the following factors, among others, could cause actual results to differ materially from forward-looking statements or historical performance: (i) the effect of the merger on CuriosityStream’s business relationships, operating results, and business generally; (ii) failure to realize the benefits expected from the merger; (iii) risks that the merger disrupts CuriosityStream’s current plans and operations and potential difficulties in CuriosityStream’s employee retention as a result of the merger; (iv) the effects of pending and future legislation; (viii) risks related to CuriosityStream’s limited operating history; (ix) the amount of the costs, fees, expenses and other charges related to the merger; (x) risks of the internet, online commerce and media industry; (xi) the highly competitive nature of the internet, online commerce and media industry and CuriosityStream’s ability to compete therein; (xii) litigation, complaints, and/or adverse publicity; (xiii) the ability to meet Nasdaq’s listing standards and (ix) privacy and data protection laws, privacy or data breaches, or the loss of data.

Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements, which are prepared in accordance with GAAP, we present EBITDA in this press release. Our use of non-GAAP financial measures has limitations as an analytical tool, and these measures should not be considered in isolation or as a substitute for analysis of financial results as reported under GAAP.

We use this non-GAAP financial measure in conjunction with financial measures prepared in accordance with GAAP for planning purposes, including in the preparation of our annual operating budget, as a measure of our core operating results and the effectiveness of our business strategy, and in evaluating our financial performance. This measure provides consistency and comparability with past financial performance, facilitates period-to-period comparisons of core operating results, and also facilitates comparisons with other peer companies, many of which use similar non-GAAP financial measures to supplement their GAAP results. In addition, EBITDA is widely used by investors and securities analysts to measure a company’s operating performance. We exclude the following items from one or more of our non-GAAP financial measures: other income, income taxes, and depreciation and amortization.

Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. In particular, (1) stock-based compensation expense has recently been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy, (2) although depreciation and amortization expense are non-cash charges, the assets subject to depreciation and amortization may have to be replaced in the future, and EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements, and (3) EBITDA does not reflect: (a) changes in, or cash requirements for, our working capital needs; (b) or tax payments that may represent a reduction in cash available to us. The non-GAAP measure we use may be different from non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes. We compensate for these limitations by providing specific information regarding the GAAP items excluded from these non-GAAP financial measures. A reconciliation of these non-GAAP measures has been provided in the financial statement tables included in this press release and investors are encouraged to review the reconciliation.

About CuriosityStream

Launched by media visionary John Hendricks, CuriosityStream is one of the world’s leading global factual streaming services and media companies. Our documentary series and features cover every topic from space exploration to adventure to the secret life of pets, empowering viewers of all ages to fuel their passions and explore new ones. With thousands of titles, many in Ultra HD 4K, including exclusive originals, CuriosityStream features stunning visuals and unrivaled storytelling to demystify science, nature, history, technology, society, and lifestyle. CuriosityStream programming is available worldwide to watch on TV, desktop, mobile and tablets. Find us on Roku, Apple TV Channels and Apple TV, Xbox One, Amazon Fire TV, Google Chromecast, iOS and Android, as well as Amazon Prime Video Channels, YouTube TV, Sling TV, DISH, Comcast Xfinity on Demand, Cox Communications, Altice USA, Suddenlink, T- Mobile, Frndly TV, Vidgo, Sony, LG, Samsung and VIZIO smart TVs, Liberty Global, Com Hem, MultiChoice, StarHub TV, Totalplay, Millicom, Okko, Gazprom and other global distribution partners and platforms. For more information, visit CuriosityStream.com.

CuriosityStream Inc.

Unaudited Statements of Operations

(in thousands, except for per share data)

 

 

 

For the three months ended

September 30,

 

For the nine months ended

September 30,

 

 

2020

 

2019

 

2020

 

2019

 

 

 

 

 

 

 

 

 

Revenues

 

$

8,744

 

 

$

4,791

 

 

$

28,260

 

 

$

11,336

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues

 

 

3,411

 

 

 

1,946

 

 

 

10,748

 

 

 

4,384

 

Advertising and marketing

 

 

7,800

 

 

 

9,410

 

 

 

28,673

 

 

 

26,124

 

General and administrative

 

 

4,286

 

 

 

3,539

 

 

 

12,191

 

 

 

10,388

 

 

 

 

15,497

 

 

 

14,895

 

 

 

51,612

 

 

 

40,896

 

Operating loss

 

 

(6,753

)

 

 

(10,104

)

 

 

(23,352

)

 

 

(29,560

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

 

 

 

 

 

Interest and other income (expense)

 

 

101

 

 

 

475

 

 

 

519

 

 

 

1,719

 

Loss before income taxes

 

 

(6,652

)

 

 

(9,629

)

 

 

(22,833

)

 

 

(27,841

)

Provision for income taxes

 

 

41

 

 

 

30

 

 

 

118

 

 

 

103

 

Net loss

 

$

(6,693

)

 

$

(9,659

)

 

$

(22,951

)

 

$

(27,944

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Less preferred dividends and accretion of issuance costs (Note 6)

 

 

(4,523

)

 

 

(4,059

)

 

 

(13,114

)

 

 

(11,725

)

Net loss attributable to common stockholders

 

$

(11,216

)

 

$

(13,718

)

 

$

(36,065

)

 

$

(39,669

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share attributable to common stockholders

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

 

(0.56

)

 

 

(0.69

)

 

 

(1.80

)

 

 

(1.98

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding

 

 

 

 

 

 

 

 

 

 

 

 

CuriosityStream Inc.

Balance Sheets

(in thousands, except par value)

 

 

September 30,

 

December 31,

 

 

2020

 

2019

 

 

(unaudited)

 

 

Assets

 

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

Cash and cash equivalents

 

$

3,374

 

 

$

8,819

 

Restricted cash

 

 

5,000

 

 

 

 

Short-term investments

 

 

12,114

 

 

 

35,525

 

Accounts receivable

 

 

5,800

 

 

 

1,777

 

Other current assets

 

 

2,951

 

 

 

2,460

 

Total current assets

 

 

29,239

 

 

 

48,581

 

 

 

 

 

 

 

 

Investments

 

 

2,770

 

 

 

15,654

 

Property and equipment, net

 

 

1,358

 

 

 

1,451

 

Content assets, net

 

 

23,826

 

 

 

16,627

 

Other assets

 

 

2,790

 

 

 

151

 

Total assets

 

$

59,983

 

 

$

82,464

 

 

 

 

 

 

 

 

Liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit)

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

Current content liabilities

 

$

2,165

 

 

$

3,306

 

Accounts payable

 

 

2,323

 

 

 

5,245

 

Accrued expenses and other liabilities

 

 

2,542

 

 

 

2,266

 

Deferred revenue

 

 

8,885

 

 

 

7,101

 

Line of credit

 

 

950

 

 

 

 

Total current liabilities

 

 

16,865

 

 

 

17,918

 

 

 

 

 

 

 

 

Non-current deferred rent liability

 

 

905

 

 

 

824

 

 

 

 

 

 

 

 

Total liabilities

 

 

17,770

 

 

 

18,742

 

 

 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

Redeemable convertible preferred stock, $0.01 par value, 30,000 shares authorized at September 30, 2020 and December 31, 2019; aggregate liquidation preference of $175,104 and $162,514 as of September 30, 2020 and December 31, 2019, respectively; 14,557 shares issued and outstanding at September 30, 2020 and December 31, 2019

 

 

168,288

 

 

 

155,174

 

 

 

 

 

 

 

 

Stockholders’ equity (deficit)

 

 

 

 

 

 

Class A Common stock, $0.01 par value – 50,000 shares authorized at September 30, 2020 and December 31, 2019, respectively; 14 and nil shares issued and outstanding at September 30, 2020 and December 31, 2019 respectively

 

 

 

 

 

 

Class B Common stock, $0.01 par value – 25,000 shares authorized at September 30, 2020 and December 31, 2019; 20,000 shares issued and outstanding at September 30, 2020 and December 31, 2019

 

 

200

 

 

 

200

 

Additional paid-in capital

 

 

 

 

 

 

Accumulated other comprehensive income

 

 

55

 

 

 

189

 

Accumulated deficit

 

 

(126,330

)

 

 

(91,841

)

Total stockholders’ equity (deficit)

 

 

(126,075

)

 

 

(91,452

)

 

 

 

 

 

 

 

Total liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit)

 

$

59,983

 

 

$

82,464

 

CuriosityStream Inc.

Unaudited Statements of Cash Flows

(in thousands)

 

 

For the nine months

ended September 30,

 

 

2020

 

2019

Cash flows from operating activities

 

 

 

 

Net loss

 

$

(22,951

)

 

$

(27,944

)

Adjustments to reconcile net loss to net cash used in operating activities

 

 

 

 

 

 

Additions to content assets

 

 

(14,004

)

 

 

(12,029

)

Change in content liabilities

 

 

(1,141

)

 

 

1,241

 

Amortization of content assets

 

 

6,805

 

 

 

2,441

 

Amortization, depreciation and accretion

 

 

399

 

 

 

64

 

Stock-based compensation

 

 

1,540

 

 

 

671

 

Changes in operating assets and liabilities

 

 

 

 

 

 

Accounts receivable

 

 

(4,023

)

 

 

(244

)

Other assets

 

 

(773

)

 

 

945

 

Accounts payable

 

 

(3,263

)

 

 

1,460

 

Accrued expenses and other liabilities

 

 

124

 

 

 

407

 

Deferred revenue

 

 

1,784

 

 

 

1,253

 

Net cash used in operating activities

 

 

(35,503

)

 

 

(31,735

)

 

 

 

 

 

 

 

Cash flows from investing activities

 

 

 

 

 

 

Purchases of property and equipment

 

 

(299

)

 

 

(590

)

Sales of investments

 

 

39,744

 

 

 

30,309

 

Maturities of investments

 

 

8,500

 

 

 

7,947

 

Purchase of investments

 

 

(12,227

)

 

 

(48,243

)

Net cash provided by (used in) investing activities

 

 

35,718

 

 

 

(10,577

)

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

Exercise of stock options

 

 

36

 

 

 

 

Borrowings on line of credit

 

 

8,250

 

 

 

 

Repayments on line of credit

 

 

(7,300

)

 

 

 

Payment of offering costs

 

 

(1,646

)

 

 

 

Net cash used in financing activities

 

 

(660

)

 

 

 

 

 

 

 

 

 

 

Net decrease in cash, cash equivalents and restricted cash

 

 

(445

)

 

 

(42,312

)

Cash, cash equivalents and restricted cash, beginning of period

 

 

8,819

 

 

 

62,516

 

Cash, cash equivalents and restricted cash, end of period

 

$

8,374

 

 

$

20,204

 

 

 

 

 

 

 

 

Supplemental schedule of non-cash financing activities:

 

 

 

 

 

 

Preferred dividends and accretion of issuance costs

 

$

13,114

 

 

$

11,725

 

Reconciliation of GAAP Financial Metrics to Non-GAAP
(in thousands)
(unaudited)
 
Reconciliation of Net Loss to EBITDA
 

For the three months ended

September 30,

 

For the nine months ended

September 30,

 

2020

 

 

 

2019

 

 

 

2020

 

 

 

2019

 

 
Net loss

$

(6,693

)

$

(9,659

)

$

(22,951

)

$

(27,944

)

Other income

 

(101

)

 

(475

)

 

(519

)

 

(1,719

)

Income taxes

 

41

 

 

30

 

 

118

 

 

103

 

Depreciation and amortization

 

83

 

 

63

 

 

256

 

 

170

 

EBITDA

$

(6,670

)

$

(10,041

)

$

(23,096

)

$

(29,390

)

 

CuriosityStream Public Relations:

Vanessa Gillon

[email protected]

CuriosityStream Investor Relations:

Denise Garcia

[email protected]

KEYWORDS: United States North America Maryland

INDUSTRY KEYWORDS: Film & Motion Pictures Online General Entertainment Entertainment TV and Radio

MEDIA:

Logo
Logo

Laird Superfood Reports Third Quarter 2020 Financial Results

Laird Superfood Reports Third Quarter 2020 Financial Results

Net Sales Increased to $7.6 Million, up 118% Year-Over-Year

Completed Initial Public Offering, Raising $64.1 Million of Net Cash

National Roll Out of Laird Superfood Liquid Creamer in Q320

SISTERS, Ore.–(BUSINESS WIRE)–
Laird Superfood, Inc. (NYSE American: LSF) (“Laird Superfood”), today reported financial results for its third quarter ended September 30, 2020.

Third Quarter 2020 Highlights

  • Net Sales increased to $7.6 million, an increase of 118% year over year.
  • Online sales contributed 49% of net sales, with lairdsuperfood.com sales growing 115% year over year.
  • Wholesale sales contributed 50%, increasing 223% year over year, as retail door expansion reached approximately 7,200 locations.
  • Liquid creamer rolled out to more than 1,200 locations, including Whole Foods and Kroger.
  • Gross profit was $1.9 million and gross margin was 24.7%, compared to gross profit of $1.5 million and a gross margin of 41.9% in the prior year period.
  • Net loss attributable to common stockholders was $4.0 million, or $0.86 per diluted share, compared to net loss of $2.4 million, or $0.66 per diluted share in the prior year period.

Paul Hodge Jr., Co-founder, President and Chief Executive Officer of Laird Superfood, commented, “The third quarter of 2020, our first quarter as a publicly traded company, was a record quarter for us with 118% year over year revenue growth, reflecting continued strength across the business. Our plant-based superfood products appeal to the growing desire for high quality, all-natural whole food ingredients that are also sustainably sourced and packaged.”

Hodge Jr. continued, “We are in the early stages of a long-term growth strategy built on market penetration into billion dollar-plus addressable markets like creamer, coffee and hydration. As a native digital platform, our loyal customer community continues to grow, reflecting the authenticity associated with the Laird Superfood brand. Mahalo to our dedicated team who achieved so much so far this year, despite adapting quickly through the pandemic, while staying focused on our operating goals and true to our culture and values.”

For the Three Months Ended September 30, 2020

 
Three Months Ended September 30,

2020

2019

$ % of Total $ % of Total
Coffee Creamers

$

5,223,724

 

69

%

$

2,224,596

 

64

%

Hydration and Beverage Enhancing Supplements

 

1,031,834

 

14

%

 

633,264

 

18

%

Coffee, Tea, and Hot Chocolate Products

 

2,188,022

 

29

%

 

578,379

 

16

%

Other

 

168,720

 

2

%

 

139,096

 

4

%

Gross Sales

 

8,612,300

 

114

%

 

3,575,335

 

102

%

Shipping income

 

25,737

 

0

%

 

132,033

 

4

%

Returns and discounts

 

(1,024,964

)

-14

%

 

(220,033

)

-6

%

Sales, net

$

7,613,073

 

100

%

$

3,487,335

 

100

%

 
Three Months Ended September 30,

2020

2019

$ % of Total $ % of Total
Online

$

3,713,773

 

49

%

$

2,229,878

 

64

%

Wholesale

 

3,773,285

 

50

%

 

1,168,306

 

34

%

Food Service

 

126,015

 

1

%

 

89,151

 

2

%

Sales, net

$

7,613,073

 

100

%

$

3,487,335

 

100

%

Net sales increased 118% to $7.6 million in the third quarter of 2020 compared to $3.5 million in the third quarter of 2019.Growth in net sales in the third quarter of 2020 was driven primarily by a combination of growth in online and wholesale channels, primarily caused by an increase in sales volume across product lines.

Gross profit was $1.9 million compared to $1.5 million in the prior year period. Gross margin was 24.7% of net sales in the third quarter of 2020, compared to 41.9% of net sales in the prior year period. The decrease in gross margin was primarily due to disposal costs related to the early production and distribution of the liquid creamer product line, elevated outbound shipping costs, and increased co-packing costs primarily associated with the liquid creamer product line.

Operating expenses of $5.3 million compared to $3.9 million in the year ago period reflect General and Administrative expense increases of $843,000, primarily related to the Company’s Initial Public Offering, as well as Sales and Marketing expense increases of $554,000, primarily related to a stock option modification expense.

Loss from operations was $3.4 million in the third quarter of 2020, compared to a loss of $2.4 million in the prior year period.

Net loss attributable to common stockholders was $4.0 million, or $0.86 per diluted share, in the third quarter of 2020, compared to a loss of $2.4 million, or $0.66 per diluted share, in the prior year period.

Valerie Ells, Chief Financial Officer, commented, “We are thrilled with our record net sales performance in the third quarter, which furthers our conviction in the strength of our brand and the compelling addressable market opportunities in front of us. Market share and customer growth are our major priorities and this quarter demonstrated that our authentic brand, and meeting consumers where they are across our omnichannel platform, resonates with today’s consumer seeking healthy, plant-based and sustainable products. We remain confident in our ability to leverage our fixed cost structure as we focus on driving the top line while taking steps toward long-term profitability.”

For the Nine Months Ended September 30, 2020

 
Nine Months Ended September 30,

2020

2019

$ % of Total $ % of Total
Coffee Creamers

$

13,241,592

 

71

%

$

5,933,639

 

66

%

Hydration and Beverage Enhancing Supplements

 

2,881,132

 

15

%

 

1,475,051

 

16

%

Coffee, Tea, and Hot Chocolate Products

 

4,167,163

 

22

%

 

1,309,524

 

15

%

Other

 

368,983

 

2

%

 

346,210

 

4

%

Gross Sales

 

20,658,870

 

110

%

 

9,064,424

 

101

%

Shipping income

 

221,082

 

1

%

 

329,342

 

4

%

Returns and discounts

 

(2,174,824

)

-11

%

 

(461,124

)

-5

%

Sales, net

$

18,705,128

 

100

%

$

8,932,642

 

100

%

 

2020

2019

$ % of Total $ % of Total
Online

$

10,049,039

 

54

%

$

5,325,768

 

60

%

Wholesale

 

8,324,286

 

45

%

 

3,449,941

 

39

%

Food Service

 

331,803

 

1

%

 

156,933

 

1

%

Sales, net

$

18,705,128

 

100

%

$

8,932,642

 

100

%

Net sales increased 109% to $18.7 million for the nine months ended September 30, 2020 compared to $8.9 million in the prior year period.

Gross profit was $5.3 million, or 28.4% of net sales, for the nine months ended September 30, 2020, compared to $3.6 million, or 40.7% of net sales, in the prior year period. The increase in gross profit was primarily due to sales growth. The decrease in gross margin was primarily due to elevated inbound freight expenses in response to an unanticipated increase in demand associated with COVID-19, elevated disposal costs related to the early production and distribution of the new liquid creamer product line and increased co-packing costs primarily associated with the liquid creamer product line.

Operating expenses of $13.7 million compared to $10.2 million in the year ago period reflect General and Administrative expense increases of $1.9 million, primarily related to the Company’s Initial Public Offering and an asset impairment recorded during the second quarter, as well as Sales and Marketing increases of $1.5 million, primarily related to stock option modification expense and increased advertising and payroll expenses.

Loss from operations was $8.4 million for the nine months ended September 30, 2020, compared to $6.5 million in the prior year period.

Net loss attributable to common stockholders was $10.0 million, or $2.26 per diluted share, for the nine months ended September 30, 2020 compared to $6.3 million, or $1.79 per diluted share, in the prior year period.

Balance Sheet and Cash Flow Highlights

The Company’s cash and cash equivalents were $72.9 million as of September 30, 2020 and total outstanding debt was $51,000. Cash and cash equivalents as of September 30, 2020 includes the net proceeds from the Company’s IPO. Net cash used in operating activities was $7.1 million in the nine months ended September 30, 2020, compared to $6.9 million in the prior year period.

Capital expenditures totaled $875,000 for the nine months ended September 30, 2020, compared to $1.6 million in the prior year period.

Successful Initial Public Offering

On September 25, 2020, the Company completed its initial public offering (“IPO”), in which it issued and sold 3,047,500 shares of common stock at a public offering price of $22.00 per share for net proceeds to the Company of approximately $62.1 million, after deducting underwriting discounts, commissions and estimated offering expenses. Danone Manifesto Ventures purchased $2.0 million of the Company’s common stock in a private placement immediately subsequent to the consummation of the IPO, at a price per share of $22.00. The Company continues to expect to use the net proceeds from the IPO for working capital and general corporate purposes, including operating expenses and capital expenditures. Additionally, the Company may use a portion of the net proceeds to acquire businesses or products. On September 30, 2020, subsequent to the IPO, there were 8,874,890 shares of common stock outstanding.

Conference Call and Webcast Details

The Company will host a conference call and webcast at 5:00 p.m. ET today to discuss the results. The live conference call can be accessed by dialing (833) 772-0381 from the U.S. or (236) 384-2050 internationally and using access code 1754637. Alternatively, participants may access the live webcast on the Laird Superfood Investor Relations website at https://investors.lairdsuperfood.com under “Events.”

About Laird Superfood

Laird Superfood, Inc. creates award-winning, plant-based superfood products that are both delicious and functional. The Company’s products are designed to enhance your daily ritual and keep consumers fueled naturally throughout the day. The Company was co-founded in 2015 by the world’s most prolific big-wave surfer, Laird Hamilton. Laird Superfood’s offerings are environmentally conscientious, responsibly tested, and made with real ingredients. Shop all products online at lairdsuperfood.com and join the Laird Superfood community on social media for the latest news and daily doses of inspiration.

Forward-Looking Statements

This press release and the earnings call referencing this press release contain “forward-looking” statements, as that term is defined under the federal securities laws, including but not limited to statements regarding Laird Superfood’s future financial performance, including our outlook for fiscal year 2020. These forward-looking statements are based on Laird Superfood’s current assumptions, expectations and beliefs and are subject to substantial risks, uncertainties, assumptions and changes in circumstances that may cause Laird Superfood’s actual results, performance or achievements to differ materially from those expressed or implied in any forward-looking statement.

The risks and uncertainties referred to above include, but are not limited to: (1) the effects of the current COVID-19 pandemic, or of other global outbreaks of pandemics or contagious diseases or fear of such outbreaks, including on our supply chain, the demand for our products, and on overall economic conditions and consumer confidence and spending levels; (2) our expectations regarding our revenue, expenses and other operating results; (3) our ability to acquire new customers and successfully retain existing customers; (4) our ability to attract and retain our suppliers, distributors and co-manufacturers; (5) our expectations regarding real or perceived quality with our products or other issues that adversely affect our brand and reputation; (6) our ability to innovate on a cost-effective basis, predict changes in consumer preferences and develop successful new products and marketing strategies in response; (7) expectations regarding prices and availability of raw materials and other inputs, a substantial amount of which come from a limited number of suppliers outside the United States, including in areas which may be adversely affected by climate change; (8) effects of changes in the tastes and preferences of our consumers and consumer preferences for natural and organic food products; (9) the financial condition of, and our relationships with, our suppliers, co-manufacturers, distributors, retailers and foodservice customers, as well as the health of the foodservice industry generally; (10) effects of real or perceived quality or health issues with our products or other issues that adversely affect our brand and reputation; (11) the ability of ourselves, our suppliers and co-manufacturers to comply with food safety, environmental or other laws or regulations; (12) our plans for future investments in our business, our anticipated capital expenditures and our estimates regarding our capital requirements; (13) the costs and success of our marketing efforts, and our ability to promote our brand; (14) our reliance on key personnel and our ability to identify, recruit and retain skilled and general working personnel; (15) our ability to effectively manage our growth; (16) our ability to compete effectively with existing competitors and new market entrants; (17) the impact of adverse economic conditions; and (18) the growth rates of the markets in which we compete.

LAIRD SUPERFOOD, INC.
STATEMENTS OF OPERATIONS
(Unaudited)
 
For the Three Months Ended
September 30,
For the Nine Months Ended
September 30,

2020

2019

2020

2019

Sales, net

$

7,613,073

 

$

3,487,335

 

$

18,705,128

 

$

8,932,642

 

Cost of goods sold

 

(5,734,144

)

 

(2,026,930

)

 

(13,384,880

)

 

(5,296,485

)

Gross profit

 

1,878,929

 

 

1,460,405

 

 

5,320,248

 

 

3,636,157

 

 
General and administrative
Salaries, wages and benefits

 

1,031,425

 

 

637,913

 

 

2,652,500

 

 

1,758,080

 

Stock-based compensation

 

290,148

 

 

145,281

 

 

589,600

 

 

436,996

 

Professional fees

 

274,244

 

 

143,424

 

 

647,422

 

 

362,134

 

Office expense

 

142,269

 

 

125,594

 

 

364,518

 

 

306,075

 

Occupancy

 

57,378

 

 

52,095

 

 

167,151

 

 

95,985

 

Merchant service fees

 

103,306

 

 

44,100

 

 

248,355

 

 

111,683

 

Netsuite subscription expense

 

33,173

 

 

35,125

 

 

90,491

 

 

112,559

 

Impairment on asset held for sale

 

 

 

 

 

239,734

 

 

 

Other expense

 

286,876

 

 

192,770

 

 

651,061

 

 

526,289

 

Total general and administrative expenses

 

2,218,819

 

 

1,376,302

 

 

5,650,832

 

 

3,709,801

 

 
Research and product development
Salaries, wages and benefits

 

54,454

 

 

77,970

 

 

202,287

 

 

132,691

 

Stock-based compensation

 

2,310

 

 

2,045

 

 

6,694

 

 

5,549

 

Other expense

 

46,115

 

 

29,963

 

 

155,009

 

 

48,172

 

Total research and product development expenses

 

102,879

 

 

109,978

 

 

363,990

 

 

186,412

 

 
Sales and marketing
Salaries, wages and benefits

 

613,961

 

 

744,964

 

 

2,057,517

 

 

1,930,485

 

Stock-based compensation

 

520,022

 

 

70,271

 

 

630,456

 

 

101,150

 

General marketing

 

325,033

 

 

525,521

 

 

895,917

 

 

1,279,391

 

Advertising

 

1,250,169

 

 

730,912

 

 

3,340,592

 

 

1,998,131

 

Amazon selling fee

 

179,425

 

 

159,153

 

 

575,313

 

 

386,648

 

Travel expense

 

4,908

 

 

82,937

 

 

78,872

 

 

266,978

 

Other expense

 

45,543

 

 

71,322

 

 

148,911

 

 

302,517

 

Total sales and marketing expenses

 

2,939,061

 

 

2,385,080

 

 

7,727,578

 

 

6,265,300

 

Total expenses

 

5,260,759

 

 

3,871,360

 

 

13,742,400

 

 

10,161,513

 

Operating loss

 

(3,381,830

)

 

(2,410,955

)

 

(8,422,152

)

 

(6,525,356

)

 
Other income (expense)
Interest and dividend income

 

20,496

 

 

56,602

 

 

51,521

 

 

149,332

 

Gain on sale of available-for-sale securities

 

6,250

 

 

 

 

13,927

 

 

 

Interest expense

 

 

 

(18,829

)

 

 

 

(18,829

)

Grant income

 

 

 

 

 

 

 

50,000

 

Total other income

 

26,746

 

 

37,773

 

 

65,448

 

 

180,503

 

Loss before income taxes

 

(3,355,084

)

 

(2,373,182

)

 

(8,356,704

)

 

(6,344,853

)

Benefit from income taxes

 

 

 

 

 

 

 

 

Net loss

$

(3,355,084

)

$

(2,373,182

)

$

(8,356,704

)

$

(6,344,853

)

Less deemed dividend of beneficial conversion feature

 

 

 

 

 

825,366

 

 

 

Less deemed dividend on warrant discount

 

(645,939

)

 

 

 

(825,366

)

 

 

Net loss attributable to Laird Superfood, Inc. common stockholders

$

(4,001,023

)

$

(2,373,182

)

$

(8,356,704

)

$

(6,344,853

)

 
Net loss per share attributable to Laird Superfood, Inc common stockholders:
Basic

$

(0.86

)

$

(0.66

)

$

(1.89

)

$

(1.79

)

Diluted

$

(0.86

)

$

(0.66

)

$

(1.89

)

$

(1.79

)

Weighted-average shares of common stock outstanding used in computing net loss per share of common stock

 

4,672,041

 

 

3,592,735

 

 

4,427,114

 

 

3,541,001

 

LAIRD SUPERFOOD, INC.
STATEMENTS OF CASH FLOWS
(Unaudited)
 
For the Nine Months Ended
September 30,

2020

2019

Cash flows from operating activities
Net loss

$

(8,356,704

)

$

(6,344,853

)

Adjustments to reconcile net loss to net cash from operating activities:
Depreciation

 

344,162

 

 

198,970

 

Loss on disposal of equipment

 

 

 

483

 

Stock-based compensation

 

1,382,864

 

 

546,475

 

Noncash conversion of note payable to grant income

 

 

 

(50,000

)

Impairment on asset held for sale

 

239,734

 

 

 

Gain on sale of investment securities available-for-sale

 

13,927

 

 

 

Changes in operating assets and liabilities:
Accounts receivable

 

(397,669

)

 

(214,122

)

Inventory

 

(1,441,766

)

 

(1,402,745

)

Prepaid expenses and other current assets

 

(1,582,315

)

 

(61,736

)

Deferred rent

 

270,731

 

 

163,365

 

Deposits

 

33,009

 

 

3,115

 

Other assets

 

7,599

 

 

3,528

 

Accounts payable

 

1,613,754

 

 

(166,799

)

Payroll liabilities

 

207,675

 

 

318,513

 

Accrued expenses

 

567,103

 

 

62,447

 

Net cash from operating activities

 

(7,097,896

)

 

(6,943,359

)

 
Cash flows from investing activities
Purchase of property, equipment, and software

 

(874,764

)

 

(1,645,800

)

Deposits on equipment to be acquired

 

 

 

(338,560

)

Sale of investment securities available-for-sale

 

516,459

 

 

 

Purchase of investment securities available-for-sale

 

 

 

(13,445,050

)

Proceeds from maturities of investment securities available-for-sale

 

4,475,000

 

 

7,004,232

 

Net cash from investing activities

 

4,116,695

 

 

(8,425,178

)

 
Cash flows from financing activities
Issuance of common stock

 

66,104,477

 

 

6,663,910

 

Issuance of preferred stock

 

10,000,006

 

 

 

Common stock repurchases

 

(20,532

)

 

(1,079,878

)

Stock options exercised

 

119,838

 

 

34,667

 

Common stock issuance costs

 

(1,131,291

)

 

 

Preferred stock issuance costs

 

(147,721

)

 

(52,073

)

Net cash from financing activities

 

74,924,777

 

 

5,566,626

 

 
Net change in cash and cash equivalents

 

71,943,576

 

 

(9,801,911

)

Cash and cash equivalents, beginning of period

 

1,004,109

 

 

17,340,023

 

Cash and cash equivalents, end of period

$

72,947,685

 

$

7,538,112

 

 
Supplemental disclosures of cash flow information
Interest paid

$

 

$

18,829

 

Supplemental disclosures of non-cash information
Unrealized gain on available-for-sale securities

$

924

 

$

56,081

 

Purchases of equipment included in deposits at the beginning of the period

$

14,699

 

$

4,577

 

 
Purchases of land included in prepaids and other current assets at the
beginning of the period

$

 

$

40,000

 

LAIRD SUPERFOOD, INC.
BALANCE SHEETS
(Unaudited)
 
As of
September 30, 2020 December 31, 2019
Assets
Current assets
Cash and cash equivalents

$

72,947,685

 

$

1,004,109

 

Accounts receivable, net

 

782,475

 

 

384,806

 

Investment securities available-for-sale

 

480,747

 

 

5,485,209

 

Inventory

 

3,877,731

 

 

2,435,965

 

Prepaid expenses and other current assets

 

2,173,123

 

 

590,808

 

Deposits

 

95,619

 

 

143,327

 

Total current assets

 

80,357,380

 

 

10,044,224

 

 
Noncurrent assets
Property and equipment, net

 

3,208,853

 

 

3,153,286

 

Fixed assets held for sale

 

250,000

 

 

 

Licensing agreement – intangible

 

132,100

 

 

132,100

 

Deferred rent

 

2,786,701

 

 

3,057,432

 

Other assets

 

7,544

 

 

15,143

 

Total noncurrent assets

 

6,385,198

 

 

6,357,961

 

Total assets

$

86,742,578

 

$

16,402,185

 

 
Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit)
Current liabilities
Accounts payable

$

2,338,505

 

$

724,751

 

Payroll liabilities

 

698,767

 

 

491,092

 

Accrued expenses

 

868,149

 

 

301,046

 

Total current liabilities

 

3,905,421

 

 

1,516,889

 

 
Long-term liabilities
Note payable

 

51,000

 

 

51,000

 

Total long-term liabilities

 

51,000

 

 

51,000

 

Total liabilities

 

3,956,421

 

 

1,567,889

 

 
Commitments and contingencies (Note 9)
 
Convertible preferred stock
Preferred stock, $0.001 par value, 5,000,000 and 1,329,680 shares authorized
as of September 30, 2020 and December 31, 2019, respectively;
Series A-1 Preferred Stock, 0 shares authorized, issued, and outstanding
as of September 30, 2020; 1,177,426 shares authorized,162,340 issued and outstanding, and
609,078 undesignated as of December 31, 2019; Series A-2 Preferred Stock 0 shares
authorized, issued, and outstanding as of September 30, 2020; 152,253 shares
authorized, issued, and outstanding as of December 31, 2019

 

 

 

6,722,951

 

Total convertible preferred stock

 

 

 

6,722,951

 

 
Stockholders’ equity
Common stock, $0.001 par value, 100,000,000 and 9,600,000 shares authorized as of
September 30, 2020 and December 31, 2019; 9,239,638 and 8,874,890
issued and outstanding at September 30, 2020, respectively; 4,551,950
and 4,188,558 issued and outstanding at December 31, 2019, respectively

 

8,875

 

 

4,188

 

Additional paid-in capital

 

110,210,155

 

 

27,184,250

 

Accumulated other comprehensive income (loss)

 

698

 

 

(226

)

Accumulated deficit

 

(27,433,571

)

 

(19,076,867

)

Total stockholders’ equity

 

82,786,157

 

 

8,111,345

 

Total liabilities, convertible preferred stock and stockholders’ equity

$

86,742,578

 

$

16,402,185

 

 

Investors:

Ashley DeSimone

[email protected]

KEYWORDS: United States North America Oregon

INDUSTRY KEYWORDS: Restaurant/Bar Other Retail Health Supermarket Food/Beverage Online Retail Fitness & Nutrition Retail

MEDIA:

SITE Centers Declares Common Stock Dividend of $0.05 for Fourth Quarter 2020

SITE Centers Declares Common Stock Dividend of $0.05 for Fourth Quarter 2020

BEACHWOOD, Ohio–(BUSINESS WIRE)–
SITE Centers Corp. (NYSE: SITC) today declared its fourth quarter 2020 common stock dividend of $0.05 per share. The common stock dividend is payable on January 7, 2021 to shareholders of record at the close of business on December 11, 2020. This dividend payment, together with dividends previously paid by the Company in 2020, satisfy the Company’s taxable income distribution requirements for calendar year 2020, as currently projected.

About SITE Centers Corp.

SITE is an owner and manager of open-air shopping centers that provide a highly-compelling shopping experience and merchandise mix for retail partners and consumers. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Exchange under the ticker symbol SITC. Additional information about the Company is available at www.sitecenters.com. To be included in the Company’s e-mail distributions for press releases and other investor news, please click here.

Safe Harbor

SITE Centers Corp. considers portions of the information in this press release to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, both as amended, with respect to the Company’s expectation for future periods. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. For this purpose, any statements contained herein that are not historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause our results to differ materially from those indicated by such forward-looking statements, including, among other factors, the impact of the COVID-19 pandemic on the Company’s ability to manage its properties and finance its operations and on tenants’ ability to operate their businesses, generate sales and meet their financial obligations, including the obligation to pay ongoing and deferred rents; the Company’s ability to pay dividends; local conditions such as the supply of, and demand for, retail real estate space in the area; the impact of e-commerce; dependence on rental income from real property; the loss of, significant downsizing of or bankruptcy of a major tenant and the impact of any such event on rental income from other tenants and our properties; redevelopment and construction activities may not achieve a desired return on investment; our ability to buy or sell assets on commercially reasonable terms; our ability to complete acquisitions or dispositions of assets under contract; our ability to secure equity or debt financing on commercially acceptable terms or at all; impairment charges; our ability to enter into definitive agreements with regard to our financing and joint venture arrangements and the Company’s ability to satisfy conditions to the completion of these arrangements; valuation and risks relating to our joint venture and preferred equity investments; the termination of any joint venture arrangements or arrangements to manage real property and the ability to satisfy conditions of such terminations; property damage, expenses related thereto and other business and economic consequences (including the potential loss of rental revenues) resulting from extreme weather conditions or natural disasters in locations where we own properties, and the ability to estimate accurately the amounts thereof; sufficiency and timing of any insurance recovery payments related to damages from extreme weather conditions or natural disasters; any change in strategy and our ability to maintain REIT status. For additional factors that could cause the results of the Company to differ materially from those indicated in the forward-looking statements, please refer to the Company’s most recent reports on Form 10-K and Form 10-Q. The impacts of the COVID-19 pandemic may also exacerbate the risks described therein, any of which could have a material effect on the Company. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

Conor Fennerty, EVP and Chief Financial Officer

216-755-5500

KEYWORDS: United States North America Ohio

INDUSTRY KEYWORDS: Commercial Building & Real Estate Construction & Property Restaurant/Bar Supermarket Convenience Store REIT Retail Department Stores

MEDIA:

Logo
Logo

Eros STX Global Corporation Announces Details of Fiscal Year 2020 Annual General Meeting of Shareholders

Eros STX Global Corporation Announces Details of Fiscal Year 2020 Annual General Meeting of Shareholders

DOUGLAS, Isle of Man–(BUSINESS WIRE)–
Eros STX Global Corporation (“ErosSTX” or the “Company”) (NYSE: ESGC), a global entertainment company, announced today that the annual general meeting of its shareholders will be held on Monday, December 21st, 2020, beginning at 2:00 p.m., Greenwich Mean Time (GMT), virtually via the internet at www.meetingcenter.io/234058716 for the transaction of the business listed in the Company’s notice of annual meeting. The password for this meeting is EROS2020. The Company’s notice of annual meeting and form of proxy were issued on November 11th, 2020.

The Company’s notice of the annual meeting, form of proxy, annual report and accounts on Form 20-F for the year ended March 31, 2020 and the transition report and accounts on Form 20-F for the transition period from September 30, 2019 to March 31, 2020 (as amended), are available in the investor relations section of the Company’s website at http://www.erosstx.com.

Eros STX Global Corporation:

Eros STX Global Corporation, (“ErosSTX”) (NYSE: ESGC) is a global entertainment company that acquires, co-produces and distributes films, digital content & music across multiple formats such as theatrical, television and OTT digital media streaming to consumers around the world. Eros International Plc changed its name to Eros STX Global Corporation pursuant to the July 2020 merger with STX Entertainment, merging two international media and entertainment groups. The combination of one of the largest Indian OTT players and premier studio with one of Hollywood’s fastest-growing independent media companies has created an entertainment powerhouse with a presence in over 150 countries. ErosSTX delivers star-driven premium feature film and episodic content across a multitude of platforms at the intersection of the world’s most dynamic and fastest-growing global markets, including US, India, Middle East, Asia and China. The company also owns the rapidly growing OTT platform Eros Now which has rights to over 12,000 films across Hindi and regional languages and had 211.5 million registered users and 36.2 million paying subscribers as of September 30th, 2020. For further information, please visit ErosSTX.com.

Investor Contact:

Drew Borst

EVP, Investor Relations & Business Development

Eros STX Global Corporation

[email protected]

KEYWORDS: Europe Isle of Man United Kingdom

INDUSTRY KEYWORDS: Professional Services Entertainment TV and Radio Film & Motion Pictures Music Finance

MEDIA:

HireQuest Reports Financial Results for the Third Quarter of 2020

HireQuest Reports Financial Results for the Third Quarter of 2020

$800,000 Sequential Improvement in Net Income Validates Confidence that Worst of COVID-19 Impact is Over

GOOSE CREEK, S.C.–(BUSINESS WIRE)–
HireQuest, Inc. (Nasdaq: HQI), a national provider of back-office and operational support for franchised operators of on-demand and temporary staffing service providers, today reported financial results for the third quarter ended September 30, 2020.

Third Quarter 2020 Financial Summary

  • Franchise royalties of $3.2 million compared to $3.1 million in the prior year period, an increase of 2.5%.
  • Service revenue, including interest paid on aging accounts receivable, of $164,000 compared to $154,000 in the prior year period, an increase of 6.7%.
  • Total revenue of $3.4 million compared to $3.3 million in the prior year period, an increase of 2.7%.
  • Net Income was $2.0 million, or $0.15 per diluted share, compared to a net loss of $7.8 million, or $(0.60) per share last year. The prior-year quarter included $4.8 million of merger-related expenses and $683,000 of income from discontinued operations.
  • Paid first quarterly cash dividend of $0.05 per share
  • On November 11, 2020, the Board of Directors declared a quarterly cash dividend of $0.05 per share of common stock expected to be paid on December 15, 2020 to shareholders of record as of December 1, 2020 representing an annual dividend yield of 2.4%2. The company intends to pay quarterly cash dividends on its common stock each year in March, June, September and December, subject to final approval by the Board of Directors each quarter after its review of the Company’s financial performance.

System-wide sales1 (a non-GAAP operating performance metric) for the third quarter 2020 of $55.6 million compared to $74.2 million for the quarter ended September 29, 2019.

“Our franchise business model, combined with a solid balance sheet and steady cash flow, are making it possible for us to continue to deliver profitable results while navigating the ongoing challenges resulting from the global healthcare crisis,” commented Rick Hermanns, HireQuest’s President and Chief Executive Officer. “For the first time, we declared a quarterly cash dividend of $0.05 per share. Our Board has again approved a dividend this quarter, and, barring anything currently unforeseen, we expect to continue to pay a similar dividend in the future. Importantly, the payment of quarterly dividends does not rule out the possibility of future acquisitions should we find the right fit for our business. Increasingly, there are distressed businesses that make for attractive opportunities, but we continue to be highly selective as we consider potential targets.”

Mr. Hermanns continued, “During the third quarter, which is generally our strongest quarter, we saw our business stabilize. We are confident that the worst is behind us despite continued uncertainty as to the timing of a recovery in specific sectors of the economy, such as construction, hospitality and large-scale entertainment. Our franchisees have done an outstanding job adjusting their cost structure to align with demand while continuing to meet the needs of their customers. We are facing unprecedented challenges and thus far, not a single franchise has failed. We remain committed to delivering value to our shareholders and believe that a regular cash dividend underscores our confidence in the long-term prospects and resiliency of our business.”

_______________

1 Refer to “Supplemental Operating Metrics” section at the end of this press release for a definition and additional details regarding System-wide sales

2 Based on a closing stock price of $8.35 on November 11, 2020

Third Quarter 2020 Financial Results

The company’s total revenue is calculated by aggregating its revenue derived from franchise royalties and service revenue. Franchise royalties are the royalties earned from franchisees primarily on the basis of their sales to their customers. Service revenue consists of interest charged to franchisees on overdue accounts and other fees for optional services we provide our franchisees.

Franchise royalties in the third quarter of 2020 were $3.2 million compared to $3.1 million in the year-ago quarter, an increase of 2.5%. Service revenue was $164,000 compared to $154,000 in the prior-year quarter, an increase of 6.7%.

Total revenue in the third quarter of 2020 was $3.4 million compared to $3.3 million in the year-ago quarter, an increase of 2.7%, or $90,000. This increase is primarily due to the increase in franchised locations in 2020 as company-owned locations were converted to franchisees in the fourth quarter of 2019, and the results of company-owned locations are presented as discontinued operations in our financial statements.

Selling, general and administrative (“SG&A”) expenses in the third quarter of 2020 were $1.4 million compared to $7.4 million for the third quarter last year. The third quarter of 2019 included approximately $4.7 million of non-recurring, merger-related expenses. The decrease in SG&A was also driven by a decrease in expenses related to workers’ compensation costs and bad debt.

Net Income in the third quarter of 2020 was $2.0 million, or $0.15 per diluted share, compared to a net loss of $7.8 million, or $(0.60) per diluted share, in the third quarter last year. The net loss from continuing operations, which excluded discontinued operations, was $8.5 million, or $(0.65) per diluted share, in the year-ago quarter. The third quarter of 2020 did not include any discontinued operations.

Balance Sheet and Capital Structure

Cash was $10.3 million as of September 30, 2020, compared to $4.2 million at December 31, 2019.

Total assets were $49.1 million as of September 30, 2020. Total liabilities were $13.7 million.

On September 15, 2020, the company paid a quarterly cash dividend of $0.05 per share of common stock to shareholders of record as of September 1, 2020.

On November 11, 2020, the company’s Board of Directors declared a quarterly cash dividend of $0.05 per share of common stock expected to be paid on December 15, 2020 to shareholders of record as of December 1, 2020.

Conference Call

HireQuest will hold a conference call to discuss its financial results.

Date:

 

 

Thursday, November 12, 2020

Time:

 

 

4:30 p.m. Eastern time (2:30 p.m. Mountain time)

Toll-free dial-in number:

 

 

1-844-602-0380

International dial-in number:

 

 

1-862-298-0970

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization.

The conference call will be broadcast live and available for replay at https://www.webcaster4.com/Webcast/Page/2359/38301 and via the investor relations section of HireQuest’s website at www.hirequest.com.

A replay of the conference call will be available through November 26, 2020.

Toll-free replay number:

 

1-877-481-4010

International replay number:

 

1-919-882-2331

Replay Passcode:

 

38301

About HireQuest

HireQuest, Inc. is a nationwide franchisor that provides on demand labor solutions primarily in the light industrial and blue-collar segments of the staffing industry for HireQuest Direct and HireQuest franchised offices across the United States. Through our national network of approximately 138 franchisee-owned offices in 30 states and the District of Columbia, HireQuest provides employment for approximately 80,000 individuals annually that work for thousands of customers in numerous industries including construction, light industrial, manufacturing, hospitality, and event services. For more information, visit www.hirequest.com.

Important Cautions Regarding Forward-Looking Statements

This news release includes, and the company’s officers and other representatives may sometimes make or provide certain estimates and other forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act, including, among others, statements with respect to future revenue, franchise sales, system-wide sales, and the growth thereof; operating results; anticipated benefits of the merger with Command Center, Inc., or the conversion to the franchise model; intended office openings; expectations of the effect on our financial condition of claims and litigation; strategies for customer retention and growth; strategies for risk management; and all other statements that are not purely historical and that may constitute statements of future expectations. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will,” and similar references to future periods.

While the company believes these statements are accurate, forward-looking statements are not historical facts and are inherently uncertain. They are based only on the company’s current beliefs, expectations, and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. The company cannot assure you that these expectations will occur, and its actual results may be significantly different. Therefore, you should not place undue reliance on these forward-looking statements. Important factors that may cause actual results to differ materially from those contemplated in any forward-looking statements made by the company include the following: the level of demand and financial performance of the temporary staffing industry; the financial performance of the company’s franchisees; changes in customer demand; the effects of any global pandemic including the impact of the novel coronavirus disease (“COVID-19”); the extent to which the company is successful in gaining new long-term relationships with customers or retaining existing ones, and the level of service failures that could lead customers to use competitors’ services; significant investigative or legal proceedings including, without limitation, those brought about by the existing regulatory environment or changes in the regulations governing the temporary staffing industry and those arising from the action or inaction of the company’s franchisees and temporary employees; strategic actions, including acquisitions and dispositions and the company’s success in integrating acquired businesses including, without limitation, successful integration following the merger with Command Center, Inc.; disruptions to the company’s technology network including computer systems and software; natural events such as severe weather, fires, floods, and earthquakes, or man-made or other disruptions of the company’s operating systems; and the factors discussed in the “Risk Factors” section and elsewhere in the company’s most recent Annual Report on Form 10-K.

Any forward-looking statement made by the company or its management in this news release is based only on information currently available to the company and speaks only as of the date on which it is made. The company and its management disclaim any obligation to update or revise any forward-looking statement, whether written or oral, that may be made from time to time, based on the occurrence of future events, the receipt of new information, or otherwise, except as required by law.

— Tables Follow —

HireQuest, Inc.

Consolidated Balance Sheets

 

 

September 30,

2020

December 31,

2019

ASSETS

(unaudited)

 

 

Current assets

Cash

$

10,297,147

 

 

$

4,187,450

Accounts receivable, net of allowance for doubtful accounts

 

24,024,564

 

 

28,201,279

Notes receivable

 

2,144,118

 

 

 

3,419,458

Prepaid expenses, deposits, and other assets

 

1,179,333

 

 

188,560

Prepaid workers’ compensation

 

1,978,509

 

 

 

822,938

Other assets

 

 

 

201,440

Total current assets

 

39,623,671

 

 

 

37,021,125

Property and equipment, net

 

2,958,998

 

 

1,900,686

Intangible assets, net

 

186,705

 

 

 

Notes receivable, net of current portion and reserve

 

6,377,779

 

 

7,990,251

Total assets

$

49,147,153

 

 

$

46,912,062

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities

 

 

 

Accounts payable

$

5,499

 

$

253,845

Other current liabilities

 

1,664,854

 

 

 

1,893,846

Accrued benefits and payroll taxes

 

2,088,119

 

 

1,113,904

Due to franchisees

 

2,311,372

 

 

3,610,596

Risk management incentive program liability

 

1,018,994

 

 

 

1,811,917

Workers’ compensation claims liability

 

3,165,056

 

 

2,327,869

Total current liabilities

 

10,253,894

 

 

 

11,011,977

Workers’ compensation claims liability, net of current portion

 

1,743,128

 

 

1,516,633

Franchisee deposits

 

1,459,335

 

 

 

1,412,924

Deferred tax liability

 

273,185

 

 

1,688,446

Total liabilities

 

13,729,542

 

 

 

15,629,980

Commitments and contingencies

 

 

 

Stockholders’ equity

 

 

 

Preferred stock – $0.001 par value, 1,000,000 shares authorized; none issued

 

 

 

Common stock – $0.001 par value, 30,000,000 shares authorized; 13,615,605 and 13,518,036 shares issued, respectively

 

13,616

 

 

 

13,518

Additional paid-in capital

 

28,541,062

 

 

27,584,610

Treasury stock, at cost – 33,092 and -0- shares, respectively

 

(146,465

)

 

 

Retained earnings

 

7,009,398

 

 

3,683,954

Total stockholders’ equity

 

35,417,611

 

 

 

31,282,082

Total liabilities and stockholders’ equity

$

49,147,153

 

$

46,912,062

HireQuest, Inc.

Consolidated Statements of Income

(unaudited)

 

Three months ended

Nine months ended

 

September 30,

2020

 

September 29,

2019

September 30,

2020

September 29,

2019

Franchise royalties

$

3,218,606

 

 

$

3,139,158

 

 

$

9,563,135

 

 

$

9,276,714

 

Service revenue

 

164,074

 

 

153,717

 

 

840,515

 

 

727,077

 

Total revenue

 

3,382,680

 

 

 

3,292,875

 

 

 

10,403,650

 

 

 

10,003,791

 

Selling, general and administrative expenses

 

1,357,725

 

 

 

7,393,380

 

 

 

6,542,171

 

 

 

9,817,245

 

Depreciation and amortization

 

32,438

 

 

 

40,200

 

 

 

96,654

 

 

 

75,630

 

Income (loss) from operations

 

1,992,517

 

 

(4,140,705

)

 

3,764,825

 

 

110,916

 

Other miscellaneous income

 

392,709

 

 

 

504,833

 

 

 

932,254

 

 

 

751,693

 

Interest and other financing expense

 

(10,035

)

 

(106,461

)

 

(39,174

)

 

(521,838

)

Net income (loss) before income taxes

 

2,375,191

 

 

 

(3,742,333

)

 

 

4,657,905

 

 

 

340,771

 

Provision for income taxes

 

404,058

 

 

 

4,716,731

 

 

 

654,592

 

 

 

4,816,337

 

Income (loss) from continuing operations

 

1,971,133

 

 

 

(8,459,064

)

 

 

4,003,313

 

 

 

(4,475,566

)

Income from discontinued operations, net of tax

 

 

 

682,674

 

 

 

 

722,756

 

Net income (loss)

$

1,971,133

 

 

$

(7,776,390

)

 

$

4,003,313

 

 

$

(3,752,810

)

 

Basic earnings (loss) per share

 

 

 

 

 

 

 

Continuing operations

$

0.15

 

$

(0.65

)

$

0.30

 

$

(0.41

)

Discontinued operations

 

 

 

 

0.05

 

 

 

 

 

 

0.07

 

Total

$

0.15

 

$

(0.60

)

$

0.30

 

$

(0.34

)

 

 

 

 

 

 

 

 

Diluted earnings (loss) per share

Continuing operations

$

0.15

 

 

$

(0.65

)

 

$

0.30

 

 

$

(0.41

)

Discontinued operations

 

 

 

0.05

 

 

 

 

0.07

 

Total

$

0.15

 

 

$

(0.60

)

 

$

0.30

 

 

$

(0.34

)

 

 

 

 

 

 

 

 

Weightedaverage shares outstanding

 

 

 

 

Basic

 

13,573,086

 

 

12,927,634

 

 

13,551,507

 

 

10,939,318

 

Diluted

 

13,574,863

 

 

 

12,927,634

 

 

 

13,553,619

 

 

 

10,939,318

 

HireQuest, Inc.

Supplemental Operating Metrics

1 Management sometimes refers to total sales generated by its franchisees as “franchise sales.” Management also sometimes refers to sales at offices that were owned and operated by the company, not by one of its franchisees, as “company-owned sales,” all of which were sold as of September 29, 2019. Sales at company-owned offices are reflected net of costs, expenses, and taxes associated with those sales on the company’s financial statements as “Income from discontinued operations, net of tax.” The sum of franchise sales and company-owned sales is referred to as “system-wide sales,” a non-GAAP operating performance metric. In other words, system-wide sales include sales at all offices, whether owned and operated by the company or by its franchisees. While the company does not record franchise sales as revenue, management believes that information on system-wide sales is important to understanding the company’s financial performance because those sales are the basis on which the company calculates and records franchise royalty revenue, are directly related to interest charged on overdue accounts, which the company records under service revenue, and are indicative of the financial health of the franchisee base.

Company Contact:

HireQuest, Inc.

Cory Smith, CFO

(800) 835-6755

Email: [email protected]

Investor Relations Contact:

Hayden IR

Brett Maas

(646) 536-7331

Email: [email protected]

KEYWORDS: United States North America South Carolina

INDUSTRY KEYWORDS: Professional Services Human Resources

MEDIA:

Zoned Properties Reports Third Quarter 2020 Financial Results

Zoned Properties Reports Third Quarter 2020 Financial Results

Large-Scale Development Expansion Proceeds as Arizona Voters Pass Prop 207

SCOTTSDALE, Ariz.–(BUSINESS WIRE)–
Zoned Properties®, Inc. (OTCQB: ZDPY), a strategic real estate development firm whose primary mission is to provide real estate and sustainability services for the regulated cannabis industry, positioning the company for property acquisitions and revenue growth, today announced its financial results for the nine and three-month periods ended September 30, 2020.

Nine Months and Third Quarter 2020 Company Highlights

  • Zoned Properties successfully leveraged its Arizona property portfolio to receive a commitment of at least $8 Million from our Significant Tenant, to be applied toward infrastructure expansion.
  • To date, nearly $5 Million of the $8 Million committed has been invested in the expansion projects located in Arizona. Construction and development work has made significant progress toward completion of the current phase of expansion, with anticipated operational readiness in 2021.
  • Zoned Properties completed a $100,000 strategic investment into a start-up cannabis franchise organization that is now in the final stages of its anticipated launch. Zoned Properties expects to play a significant role with the cannabis franchise related to the intricacies of strategic capital investment and commercial real estate development in the regulated cannabis industry.
  • In Arizona, and across the nation, the passage of regulated cannabis ballot measures reflect the overwhelming support from the majority of American voters for the regulated cannabis industry.

Nine Months and Third Quarter 2020 Financial Results

  • Revenue decreased 10.5% to $302,772 for the third quarter of 2020, compared to $338,339 for the third quarter of 2019. This decrease in revenues was primarily attributable to a decrease in advisory revenues of $42,191, or 70.2%, offset by an increase in rent revenues of $6,624, or 2.4%.
  • Operating expenses decreased 18.1% to $249,021 for the third quarter of 2020, compared to $304,052 for the third quarter of 2019.
  • Income from operations increased 56.8% to $53,751 for the third quarter of 2020, compared to income from operations of $34,287 for the third quarter of 2019, an increase of $19,464.
  • Net income was $25,089, or $0.00 per basic and diluted share, for the third quarter of 2020, compared to net income of $3,987, or $0.00 per basic and diluted share, for the third quarter of 2019.
  • Net cash provided by operating activities was $48,470 for the nine months ended September 30, 2020, compared to $219,433 for the nine months ended September 30, 2019.
  • As of September 30, 2020, Zoned Properties had cash of $577,763, compared to $639,781 as of December 31, 2019.

“It has been an exciting year for Zoned Properties as we continue expanding our operational footprint in Arizona, developing our national advisory services with new client projects and advisory professionals, and prepare for the launch of a new cannabis franchise concept,” commented Bryan McLaren, Chief Executive Officer of Zoned Properties. “We are empowered by Arizona voters and voters across the nation, who spoke up on election day to pass regulated cannabis measures on the ballot. Our expansion projects in Arizona could not have come at a better time, as we prepare for an exciting new adult-use marketplace and the completion of new operational square footage at our facilities in Arizona will lead to a material increase in leasing revenue for Zoned Properties.”

About Zoned Properties, Inc. (OTCQB: ZDPY):

Zoned Properties is a strategic real estate development firm whose primary mission is to provide real estate and sustainability services for clients in the regulated cannabis industry, positioning the company for real estate acquisitions and revenue growth. We intend to pioneer sustainable development for emerging industries, including the regulated cannabis industry. We are an accredited member of the Better Business Bureau, the U.S. Green Building Council, and the Forbes Real Estate Council. We focus on investing capital to acquire and develop commercial properties to be leased on a triple-net basis, and engaging clients that face zoning, permitting, development, and operational challenges. We provide development strategies and advisory services that could potentially have a major impact on cash flow and property value. We do not grow, harvest, sell or distribute cannabis or any substances regulated under United States law such as the Controlled Substance Act of 1970, as amended (the “CSA”).

Website: www.ZonedProperties.com

Twitter: @ZonedProperties

LinkedIN: @ZonedProperties

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as “believe,” “expect,” “anticipate,” “plan,” “potential,” “continue” or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in the Company’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

COVID-19 Statement

In March 2020, the World Health Organization declared COVID-19 a global pandemic and recommended containment and mitigation measures worldwide. We are monitoring this closely, and although operations have not been materially affected by the COVID-19 outbreak to date, the ultimate duration and severity of the outbreak and its impact on the economic environment and our business is uncertain. Currently, all of the properties in our portfolio are open to our Significant Tenants and their customers and will remain open pursuant to state and local government requirements. At this time, we do not foresee any material changes to our operations from COVID-19. Our tenants are continuing to generate revenue at these properties and they have continued to make rental payments in full and on time and we believe the tenants’ liquidity position is sufficient to cover its expected rental obligations. Accordingly, while we do not anticipate an impact on our operations, we cannot estimate the duration of the pandemic and potential impact on our business if the properties must close or if the tenants are otherwise unable or unwilling to make rental payments. In addition, a severe or prolonged economic downturn could result in a variety of risks to our business, including weakened demand for our properties and a decreased ability to raise additional capital when needed on acceptable terms, if at all. At this time, the Company is unable to estimate the impact of this event on its operations.

Investor Relations

Zoned Properties, Inc.

Bryan McLaren

Tel (877) 360-8839

[email protected]

www.zonedproperties.com

KEYWORDS: United States North America Arizona

INDUSTRY KEYWORDS: Professional Services Retail Tobacco Commercial Building & Real Estate Construction & Property Urban Planning Consulting

MEDIA:

Logo
Logo

The LGL Group Reports Third Quarter 2020 Results

The LGL Group Reports Third Quarter 2020 Results

ORLANDO, Fla.–(BUSINESS WIRE)–
The LGL Group, Inc. (NYSE American: LGL) (the “Company” or “LGL”), announced its financial results for the three and nine months ended September 30, 2020.

  • Revenues of $8.1 million declined (6.0%) compared to Q3 2019 revenues of $8.6 million
  • Operating income was $0.7 million in Q3 2020 versus $1.1 million for the prior year period
  • Diluted net income of $0.12 per share compared to $0.91 per share ($0.24 per share excluding a $3.3 million tax benefit) for the prior year quarter
  • Order backlog was $21.5 million compared to $23.3 million at September 30, 2019
  • Adjusted EBITDA for Q3 2020 was $0.9 million compared to $1.3 million for Q3 2019
  • Warrant dividend declared October 29, 2020 providing shareholders’ efficient participation in future value.

The Company’s President and Chief Executive Officer, Ivan Arteaga, said, “I commend the team for pulling together as we worked through the spring COVID-19 shock, and ensuing summer impacts. While demand from the avionics industry has contracted significantly, the trajectory of the military/aerospace business is strong and growing. Recent orders offer promise that we are getting back to normal.”

Commenting on the Company’s Q3 2020 results, Bill Drafts, President and Chief Executive Officer of LGL’s main operating unit, MtronPTI, stated, “Our results improved sequentially quarter-to-quarter as the overall business environment began to stabilize and we could focus on the strategic actions previously planned. I would like to thank the team for their dedication and thank our customers for their continued business.”

THIRD QUARTER RESULTS – In 2020, LGL’s third quarter revenues decreased $0.5 million, or 6.0%, to $8.1 million compared to $8.6 million for the corresponding quarter in 2019. Operating income declined to $0.7 million reflecting lower sales than prior year, although sales showed improvement over second quarter 2020 levels. Product mix changes and costs related to the avionics production work slowdown also contributed to the operating profit decline. Adjusted EBITDA was $0.9 million in the third quarter of 2020 versus $1.3 million in the third quarter of 2019.

EARNINGS PER SHARE – Diluted earnings per share from ongoing operations, during the third quarter were $0.12 per share in 2020 as compared to $0.91 per share in the third quarter of 2019. The decrease was largely attributable to the $3.3 million tax benefit in 2019 primarily due to release of the valuation allowance related to the Company’s U.S. deferred tax assets and also from the operating income impacts noted above. Weighted average shares outstanding at September 30, 2020 were 5.3 million versus 5.0 million at September 30, 2019.

BALANCE SHEET – LGL’s balance sheet continued to improve in 2020. The balance sheet reflects a net cash position including marketable securities of $22.9 million at September 30, 2020 compared to $18.1 million at December 31, 2019. The Company continues to explore growth organically and through diversified merger and acquisitions and believes the relationship with the SPAC has enhanced its strategic profile in this context.

OPERATING STATISTICS – As of September 30, 2020, the Company’s backlog decreased 7.9% to $21.5 million as compared to $23.3 million at September 30, 2019.

Our summary operating statistics are as follows:

 

Three months ended

 

 

 

 

 

 

 

 

 

 

September 30,

 

 

Change

 

(Amounts in millions, except book:bill)

2020

 

 

2019

 

 

$

 

 

%

 

Bookings (Sales)

$

7,031

 

 

$

7,391

 

 

$

(360

)

 

 

(4.9

%)

Shipments (Revenues)

$

8,071

 

 

$

8,588

 

 

$

(517

)

 

 

(6.0

%)

Book:Bill

 

0.871

 

 

 

0.861

 

 

 

0.011

 

 

 

1.2

%

Backlog

$

21,456

 

 

$

23,285

 

 

$

(1,829

)

 

 

(7.9

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine months ended

 

 

 

 

 

 

 

 

 

 

September 30,

 

 

Change

 

(Amounts in millions, except book:bill)

2020

 

 

2019

 

 

$

 

 

%

 

Bookings (Sales)

$

23,347

 

 

$

28,837

 

 

$

(5,490

)

 

 

(19.0

%)

Shipments (Revenues)

$

23,748

 

 

$

23,058

 

 

$

690

 

 

 

3.0

%

Book:Bill

 

0.983

 

 

 

1.251

 

 

 

(0.268

)

 

 

(21.4

%)

About The LGL Group, Inc.

The LGL Group, Inc., through its two principal subsidiaries MtronPTI and PTF, designs, manufactures and markets highly-engineered electronic components used to control the frequency or timing of signals in electronic circuits, and designs high performance frequency and time reference standards that form the basis for timing and synchronization in various applications.

Headquartered in Orlando, Florida, the Company has additional design and manufacturing facilities in Yankton, South Dakota, Wakefield, Massachusetts and Noida, India, with local sales offices in Hong Kong and Austin, Texas.

For more information on the Company and its products and services, contact James Tivy at The LGL Group, Inc., 2525 Shader Rd., Orlando, Florida 32804, (407) 298-2000, or visit www.lglgroup.com and www.mtronpti.com.

Caution Concerning Forward Looking Statements

This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21 E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. These forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to us and our current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans, anticipated actions and our future financial condition and results. Certain of these risks and uncertainties are described in greater detail in our filings with the Securities and Exchange Commission. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

 

THE LGL GROUP, INC.

Condensed Consolidated Statements of Operations

(Unaudited)

(Dollars in Thousands, Except Share and Per Share Amounts)

 

 

 

For the Three Months Ended

September 30,

 

 

 

2020

 

 

2019

 

REVENUES

 

$

8,071

 

 

$

8,588

 

Costs and expenses:

 

 

 

 

 

 

 

 

Manufacturing cost of sales

 

 

5,203

 

 

 

5,049

 

Engineering, selling and administrative

 

 

2,159

 

 

 

2,417

 

OPERATING INCOME

 

 

709

 

 

 

1,122

 

Total other income (expense), net

 

 

91

 

 

 

82

 

INCOME BEFORE INCOME TAXES

 

 

800

 

 

 

1,204

 

Income tax expense (benefit)

 

 

171

 

 

 

(3,326

)

NET INCOME

 

$

629

 

 

$

4,530

 

 

 

 

 

 

 

 

 

 

Weighted average number of shares used in basic EPS calculation

 

 

5,212,652

 

 

 

4,901,698

 

BASIC NET INCOME PER COMMON SHARE

 

$

0.12

 

 

$

0.92

 

Weighted average number of shares used in diluted EPS calculation

 

 

5,251,078

 

 

 

4,965,808

 

DILUTED NET INCOME PER COMMON SHARE

 

$

0.12

 

 

$

0.91

 

 

 

For the Nine Months Ended

September 30,

 

 

 

2020

 

 

2019

 

REVENUES

 

$

23,748

 

 

$

23,058

 

Costs and expenses:

 

 

 

 

 

 

 

 

Manufacturing cost of sales

 

 

15,681

 

 

 

13,970

 

Engineering, selling and administrative

 

 

6,514

 

 

 

6,676

 

OPERATING INCOME

 

 

1,553

 

 

 

2,412

 

Total other income (expense), net

 

 

(204

)

 

 

353

 

INCOME BEFORE INCOME TAXES

 

 

1,349

 

 

 

2,765

 

Income tax expense (benefit)

 

 

282

 

 

 

(3,286

)

NET INCOME

 

$

1,067

 

 

$

6,051

 

 

 

 

 

 

 

 

 

 

Weighted average number of shares used in basic EPS calculation

 

 

5,159,452

 

 

 

4,872,461

 

BASIC NET INCOME PER COMMON SHARE

 

$

0.21

 

 

$

1.24

 

Weighted average number of shares used in diluted EPS calculation

 

 

5,195,754

 

 

 

4,965,989

 

DILUTED NET INCOME PER COMMON SHARE

 

$

0.21

 

 

$

1.22

 

 

THE LGL GROUP, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

(Dollars in Thousands)

 
 

 

 

September 30,

2020

 

 

December 31,

2019

 

ASSETS

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

17,276

 

 

$

12,453

 

Marketable securities

 

 

5,646

 

 

 

5,631

 

Accounts receivable, net

 

 

4,644

 

 

 

4,445

 

Inventories, net

 

 

5,430

 

 

 

6,016

 

Prepaid expenses and other current assets

 

 

268

 

 

 

365

 

Total Current Assets

 

 

33,264

 

 

 

28,910

 

Property, plant, and equipment, net

 

 

2,824

 

 

 

2,831

 

Equity investment in unconsolidated subsidiary

 

 

3,134

 

 

 

3,334

 

Deferred income taxes, net

 

 

3,046

 

 

 

3,307

 

Intangible assets, net

 

 

366

 

 

 

402

 

Right-of-use lease asset

 

 

452

 

 

 

331

 

Other assets

 

 

 

 

 

102

 

Total Assets

 

$

43,086

 

 

$

39,217

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Total Current Liabilities

 

 

3,700

 

 

 

4,324

 

Total Stockholders’ Equity

 

 

39,386

 

 

 

34,893

 

Total Liabilities and Stockholders’ Equity

 

$

43,086

 

 

$

39,217

 

Reconciliations of GAAP to Non-GAAP Measures

To supplement our consolidated financial statements presented on a GAAP (generally accepted accounting principles) basis, the Company uses certain non-GAAP measures, including Adjusted EBITDA, which we define as net income adjusted to exclude depreciation and amortization expense, interest income (expense), provision (benefit) for income taxes, stock-based compensation expense, investment income and other items we believe are discrete events which have a significant impact on comparable GAAP measures and could distort an evaluation of our normal operating performance. These adjustments to our GAAP results are made with the intent of providing both management and investors a more complete understanding of the underlying operational results and trends and our marketplace performance. The presentation of this additional information is not meant to be considered in isolation or as a substitute for net earnings or diluted earnings per share prepared in accordance with generally accepted accounting principles in the United States.

 

Reconciliation of GAAP Net Income Before Income Taxes to Non-GAAP Adjusted EBITDA:

 
 

 

 

For the Three Months Ended

September 30,

 

 

 

2020

 

 

2019

 

(000’s, except share and per share amounts)

 

 

 

 

 

 

 

 

Net income before income taxes

 

$

800

 

 

$

1,204

 

Interest expense (income)

 

 

3

 

 

 

 

Depreciation and amortization

 

 

131

 

 

 

125

 

Non-cash stock compensation

 

 

57

 

 

 

5

 

Investment income

 

 

(124

)

 

 

(76

)

Loss on equity investment in unconsolidated subsidiary

 

 

61

 

 

 

 

Adjusted EBITDA

 

$

928

 

 

$

1,258

 

 

 

 

 

 

 

 

 

 

Basic per share information:

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

5,212,652

 

 

 

4,901,698

 

Adjusted EBITDA per share

 

$

0.18

 

 

$

0.26

 

 

 

 

 

 

 

 

 

 

Diluted per share information:

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

5,251,078

 

 

 

4,965,808

 

Adjusted EBITDA per share

 

$

0.18

 

 

$

0.25

 

 

 

For the Nine Months Ended

September 30,

 

 

 

2020

 

 

2019

 

(000’s, except shares and per share amounts)

 

 

 

 

 

 

 

 

Net income before income taxes

 

$

1,349

 

 

$

2,765

 

Interest expense (income)

 

 

7

 

 

 

(1

)

Depreciation and amortization

 

 

392

 

 

 

365

 

Non-cash stock compensation

 

 

104

 

 

 

17

 

Investment income

 

 

(67

)

 

 

(346

)

Loss on equity investment in unconsolidated subsidiary

 

 

200

 

 

 

 

Adjusted EBITDA

 

$

1,985

 

 

$

2,800

 

 

 

 

 

 

 

 

 

 

Basic per share information:

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

5,159,452

 

 

 

4,872,461

 

Adjusted EBITDA per share

 

$

0.38

 

 

$

0.57

 

 

 

 

 

 

 

 

 

 

Diluted per share information:

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

5,195,754

 

 

 

4,965,989

 

Adjusted EBITDA per share

 

$

0.38

 

 

$

0.56

 

 

James Tivy

The LGL Group, Inc.

[email protected]

(407) 298-2000

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Semiconductor Technology Aerospace Manufacturing Other Manufacturing Hardware

MEDIA:

NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results

  • NGM continues to demonstrate the productivity of its research discovery engine and progress against its multi-therapeutic area pipeline:
       —   Initiated a Phase 2 clinical trial of NGM621, an anti-complement C3 antibody, in patients with geographic atrophy (GA)
       —   Announced expansion of oncology portfolio with first immuno-oncology candidate, NGM707, a novel dual antagonist antibody inhibiting ILT2 and ILT4
  • NGM has $287.9 million in cash, cash equivalents and marketable securities as of September 30, 2020
  • NGM will present first-in-human results from Phase 1 study of NGM621 in patients with GA at the upcoming American Academy of Ophthalmology (AAO) Virtual Annual Meeting on November 13, 2020
  • NGM will conduct an R&D Day showcasing its portfolio on December 9, 2020

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the quarter ended September 30, 2020.

“We made notable progress across our pipeline this past quarter, as we continue to pursue a portfolio of product candidates directed to biologically powerful targets,” said David J. Woodhouse, Ph.D., Chief Executive Officer at NGM. “Since mid-July, we have initiated a Phase 2 clinical trial of NGM621, our anti-complement C3 antibody, designed to slow disease progression in people with geographic atrophy, and we have disclosed our first immuno-oncology development candidate, NGM707, a novel dual antagonist antibody inhibiting ILT2 and ILT4, designed to potentially improve patient immune responses to tumors.”

Dr. Woodhouse continued, “We look forward to our upcoming R&D Day on December 9th, where we will showcase not only our exciting portfolio of programs but also highlight the talented NGM scientists whose expertise, creativity and passion have enabled our track record of rapid innovation and sustained productivity.”

Key
Third
Quarter and Recent Highlights

Liver and metabolic diseases

  • Completed enrollment in Phase 2b ALPINE 2/3 study of aldafermin in NASH patients. NGM completed enrollment in the Phase 2b ALPINE 2/3 clinical study of aldafermin in patients with biopsy-confirmed NASH and stage 2 or 3 (F2-F3) liver fibrosis. The 24-week study will assess the efficacy, safety and tolerability of 0.3 mg, 1 mg and 3 mg doses of aldafermin compared to placebo. The primary objective of the ALPINE 2/3 study is to evaluate a dose response showing an improvement in liver fibrosis by ≥ 1 stage with no worsening of steatohepatitis at week 24. NGM expects to report topline findings from the study in the second quarter of 2021.
  • Ongoing
    enrollment in Phase 2b ALPINE 4 study of aldafermin in NASH patients with compensated cirrhosis. NGM continued enrollment in the Phase 2b ALPINE 4 study of aldafermin in patients with biopsy-confirmed compensated NASH cirrhosis (F4). The 48-week study is designed to enroll approximately 150 patients and will assess the efficacy, safety and tolerability of 0.3 mg, 1 mg and 3 mg doses of aldafermin compared to placebo.
  • Data from 24-week double
    blind, randomized, placebo-controlled Phase 2 study (Cohort 4) of aldafermin in NASH patients
    presented at The Digital International Liver Congress

    2020
    and
    published in

    Gastroenterology

    . Cohort 4 demonstrated statistically significant dual activity in both reversing fibrosis and resolving NASH. In the study, aldafermin continued to demonstrate a favorable tolerability profile. Cohort 4 was the final reported cohort from NGM’s adaptive Phase 2 clinical study of aldafermin in NASH, and the results observed in Cohort 4 were consistent with data from the three previous cohorts.

Retinal diseases

  • Initiated Phase 2 CATALINA study of NGM621 in patients with GA. In July, NGM began the Phase 2 CATALINA study, a multicenter, randomized, double-masked, sham-controlled clinical trial to evaluate the safety and efficacy of intravitreal (IVT) injections of NGM621 in patients with GA secondary to age-related macular degeneration. NGM anticipates enrolling 240 patients diagnosed with GA in one or both eyes.
  • NGM will present
    results from a
    Phase 1
    study of
    NGM621 in patients with GA at
    the
    American Academy of Ophthalmology (AAO) Virtual Annual Meeting on November
    13, 2020 at 10:00 a.m
    .
    ET
    . NGM completed the Phase 1 study with single- and multiple-dose IVT injections of NGM621 in patients with GA. The AAO presentation will be the first-in-human data presented on NGM621 in GA.

Cancer

  • Expanded o
    ncology portfolio with
    f
    irst i
    mmuno-oncology development candidate, NGM707, a dual
    antagonist a
    ntibody i
    nhibiting ILT2 and ILT4
    . These receptors represent key myeloid and lymphoid checkpoints, and may restrict anti-tumor immunity, enable tumors to evade immune detection and contribute to T cell checkpoint resistance. NGM plans to initiate first-in-human testing of NGM707 in mid-2021 in patients with advanced solid tumors.
  • Ongoing
    enrollment in Phase 1a/1b study of NGM120 in patients with cancer anorexia/cachexia syndrome
    (CACS) and cancer. NGM continues to enroll patients in a Phase 1a/1b clinical study to evaluate NGM120, a first-in-class antagonistic antibody that binds glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) and inhibits GDF15 signaling, for the potential treatment of CACS and cancer. CACS is the uncontrolled wasting of both skeletal muscle and fat that is a common co-morbidity of cancer and is associated with shortened survival in cancer patients.

Merck Collaboration

Merck has a one-time option to license NGM pipeline programs – other than aldafermin and NGM395 – following human proof-of-concept trials under the terms of the companies’ ongoing strategic collaboration. Upon exercising any such option, Merck would lead global product development and commercialization for the resulting products, if approved. Prior to Merck initiating a Phase 3 study for a licensed program, NGM may elect to either receive milestone and royalty payments or to co-fund development and participate in a global cost and revenue share arrangement of up to 50%. The agreement also provides NGM with the option to participate in the co-promotion of any co-funded program in the United States. In January 2019, Merck exercised its first option under the collaboration to license MK-3655, previously referred to as NGM313.

Third
Quarter Financial Results

  • For the quarter ended September 30, 2020, NGM reported a net loss of $29.8 million, compared to a net loss of $10.9 million for the corresponding period in 2019.
  • Related party revenue from our collaboration with Merck for the quarter ended September 30, 2020 was $23.5 million, compared to $21.6 million for the corresponding period in 2019.
  • Research and development expenses for the quarter ended September 30, 2020 were $47.0 million, compared to $29.0 million for the corresponding period in 2019. The increase in research and development expenses was mainly attributable to increases in external research and development expenses associated with the advancement of NGM’s growing pipeline, primarily related to our aldafermin, NGM621, NGM120 and NGM707 programs, and personnel-related expenses driven by increased headcount.
  • General and administrative expenses for the quarter ended September 30, 2020 were $6.5 million, compared to $5.6 million for the corresponding period in 2019. The increase in general and administrative expenses was primarily attributable to increases in personnel-related expenses driven by increased headcount, as well as external expenses to support our operations as a public company.
  • Cash, cash equivalents and short-term marketable securities were $287.9 million as of September 30, 2020, compared to $344.5 million as of December 31, 2019.

About NGM Biopharmaceuticals, Inc.

NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases and cancer. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs in clinical development. Visit us at www.ngmbio.com for more information.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “will,” “planned,” “pursue,” “look forward,” “expects,” ‘designed to,” “anticipates,” “plans,” “potential,” “aspire” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to NGM’s intentions to present at future events; the productivity of NGM’s research and advancement of NGM’s clinical and preclinical pipeline; the continued progress of, and the timing of enrollment and results of, NGM’s clinical trials, including timing of topline results of the ALPINE 2/3 study and the presentation of data from the Phase 1 study of NGM621 in patients with GA; and the design, timing, enrollment, safety, tolerability and efficacy of, and continued development of, NGM’s product candidates, including aldafermin, NGM621, NGM707 and NGM120. Because such statements deal with future events and are based on NGM’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of NGM could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success, including risks related to failure or delays in successfully enrolling or completing clinical studies, the risk that the results obtained to date in NGM’s clinical trials may not be indicative of results obtained in subsequent pivotal or other late-stage trials, and the risk that NGM’s ongoing or future clinical studies in humans may show that aldafermin is not a tolerable and effective treatment for NASH patients; the ongoing COVID-19 pandemic, which has adversely affected, and could materially and adversely affect in the future, our business and operations; the time-consuming and uncertain regulatory approval process; NGM’s reliance on third-party manufacturers for aldafermin and its other product candidates; the sufficiency of NGM’s cash, cash equivalents and short-term marketable securities and need for additional capital; and other risks and uncertainties affecting NGM and its development programs, as well as those discussed in the sections titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” in our quarterly report on Form 10-Q for the quarter ended June 30, 2020 and future filings and reports that NGM makes from time to time with the United States Securities and Exchange Commission. Except as required by law, NGM assumes no obligation to update these forward-looking statements, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.

Investor Contact:

Alex Schwartz
[email protected]
Media Contact:

Liz Melone
[email protected]

                                     
NGM BIOPHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share amounts)

(Unaudited)
 
        Three Months Ended     Nine Months Ended  
        September
 
30,
    September
 
30,
 
        2020     2019     2020     2019  
Related party revenue $ 23,482     $ 21,568     $ 67,601     $ 72,461  
Operating expenses:                              
Research and development   46,979       28,953       123,912       87,299  
General and administrative     6,460       5,612       19,849       17,208  
Total operating expenses   53,439       34,565       143,761       104,507  
Loss from operations     (29,957 )     (12,997 )     (76,160 )     (32,046 )
Interest income     260       1,984       1,823       5,138  
Other income (expense), net     (68 )     96       (159 )     54  
Net loss   $ (29,765 )   $ (10,917 )   $ (74,496 )   $ (26,854 )
Net loss per share, basic and diluted   $ (0.43 )   $ (0.17 )   $ (1.09 )   $ (0.60 )
Weighted average shares used to compute net loss per share, basic and diluted     68,815,696       65,948,207       68,174,654       44,828,596  
 
(1)   In April 2019, the Company completed its initial public offering (IPO) and concurrent private placement with Merck Sharp & Dohme Corp., in which the Company issued an aggregate of 7,521,394 and 4,121,683 shares of common stock, respectively, and all of the then outstanding shares of convertible preferred stock were automatically converted into shares of common stock upon the closing of the IPO.

 
NGM BIOPHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands
)

(Unaudited)
 
    September
 
30,
    December
 
31,
 
    2020     2019  
Assets                
Current assets:                
Cash and cash equivalents   $ 253,976     $ 245,598  
Short-term marketable securities     33,973       98,913  
Related party receivable from collaboration     7,215       5,206  
Prepaid expenses and other current assets     7,076       5,531  
Total current assets     302,240       355,248  
Property and equipment, net     15,773       19,475  
Restricted cash     1,499       1,874  
Other non-current assets     6,570       3,806  
Total assets   $ 326,082     $ 380,403  
Liabilities and stockholders’ equity              
Current liabilities:                
Accounts payable   $ 1,613     $ 9,026  
Accrued liabilities     28,579       22,991  
Deferred rent, current     2,938       2,829  
Deferred revenue, current     4,586       4,872  
Total current liabilities     37,716       39,718  
Deferred rent, non-current     7,179       9,392  
Other non-current liabilities     4,315        
Early exercise stock option liability     169       574  
Total liabilities     49,379       49,684  
Commitments and contingencies                
Stockholders’ equity:                
Preferred stock, $0.001 par value; 10,000,000 shares authorized;
no shares issued or outstanding as of September 30, 2020 and
December 31, 2019, respectively
           
Common stock, $0.001 par value; 400,000,000 shares authorized;
68,934,767 and 66,960,279 shares issued and outstanding as of
September 30, 2020 and December 31, 2019, respectively
    69       67  
Additional paid-in capital     547,259       526,771  
Accumulated other comprehensive gain     15       25  
Accumulated deficit     (270,640 )     (196,144 )
Total stockholders’ equity     276,703       330,719  
Total liabilities and stockholders’ equity   $ 326,082     $ 380,403  

Annexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with Initiation of Huntington’s Disease Clinical Program

– First patient dosed in Phase 2 study of ANX005 C1q targeted mAb –

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the brain, body and eye, today announced that it has initiated a Phase 2 study, dosing the first patient with its full-length monoclonal antibody ANX005 in Huntington’s Disease (HD). The Phase 2 trial in HD expands Annexon’s classical complement platform into neurodegenerative diseases of the brain and highlights the pioneering research of the company’s co-founder, the late Dr. Ben Barres, former member of the National Academy of Sciences and Chair of Neurobiology, Stanford University. Aberrant activation of C1q plays a significant role in the neurodegenerative process by causing synapse loss, chronic neuroinflammation and eventual neuronal death.

“Huntington’s Disease is a devastating, progressive movement disorder with no cure and no approved therapeutic options available to patients and their families,” commented Sanjay Keswani, MBBS, BSc, FRCP, Chief Medical Officer of Annexon. “In neurodegenerative conditions like HD, our goal is to disrupt the disease course by inhibiting harmful classical complement activity, including synapse loss, that leads to neurodegeneration and cognitive impairment. We are excited to advance ANX005 and look forward to initial results from our Phase 2 trial in the second half of 2021.”

“Annexon targets the initiating protein of the classical complement pathway, C1q, which uniquely binds to synapses in the brain and appears to cause inappropriate synapse elimination during chronic neurodegenerative disease, such as HD,” stated Beth Stevens, PhD, Associate Professor of Neurology, Children’s Hospital Boston and former postdoctoral scholar in Dr. Barres’ lab. “Inhibiting C1q and protecting functioning synapses may benefit patients with neurodegenerative conditions.”

About the Clinical Trial
and ANX005

The Phase 2 open-label trial is enrolling up to 24 patients and is designed to assess safety, tolerability and biomarkers of target engagement and impact on neurodegeneration.

ANX005 is an IV formulated monoclonal antibody designed to inhibit C1q and the entire classical complement pathway. ANX005 is designed to treat patients with antibody-mediated autoimmune and complement-mediated neurodegenerative disorders. In addition to the HD indication, Annexon has completed a Phase 1b clinical trial of ANX005 in Guillain-Barré Syndrome (GBS) and has received fast track and orphan drug designations from the U.S. Food and Drug Administration for the treatment of GBS.

More information can be found at www.annexonbio.com or www.clinicaltrials.gov, identifier NCT04514367, or the HD Coalition for Patient Engagement https://www.huntingtonsociety.ca/hdcope/.        

About Annexon, Inc.

Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the brain, body and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended tissue compartments. For more information, visit www.annexonbio.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: advancement of the company’s clinical and preclinical programs and timing of clinical results; the potential benefits of inhibiting C1q; and the implementation of the company’s business model and strategic plans for its business and product candidates. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company’s history of net operating losses; the company’s ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company’s product candidates; the effects of COVID-19 or other public health crises on the company’s clinical programs and business operations; the company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the company’s product candidates; the company’s reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company’s ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled “Risk Factors” contained in the company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020 filed with the Securities and Exchange Commission (SEC) on September 9, 2020 and the company’s other filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
Sylvia Wheeler
[email protected]

Alexandra Santos
[email protected]

Media Contact:
Caroline Rufo, Ph.D.
[email protected]

SIGA Technologies Chief Scientific Officer to Participate at NCT Asia Virtual Conference on November 13, 2020

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis Hruby, Chief Scientific Officer, will participate in a panel discussion at the Non-Conventional Threats (NCT) Asia Virtual Conference.

The panel discussion titled, “COVID-19: Insights on an Epidemic Outbreak” will take place at 12:00 p.m. Malaysia Time on Friday, November 13, 2020 with Dr. Hruby speaking as one member of the panel at the conference.

“With the COVID-19 pandemic continuing its devastating global impact, preparedness for the possibility of future pandemics are of increasing importance for governments worldwide. We look forward to providing information about TPOXX in addressing a potential smallpox outbreak, which is far more lethal than COVID-19,” said Dr. Hruby.

ABOUT SIGA TECHNOLOGIES, INC. and TPOXX

®

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX® is a novel small-molecule drug and the US maintains a stockpile of 1.7 million courses in the Strategic National Stockpile under Project BioShield. The oral formulation of TPOXX® was approved by the FDA for the treatment of smallpox in 2018. The full label is here: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fce826ab-4d6a-4139-a2ee-a304a913a253. In September 2018, SIGA signed a contract potentially worth more than $600 million with BARDA for additional procurement and development related to both oral and intravenous formulations of TPOXX®. For more information about SIGA, please visit www.siga.com.

About Smallpox

1

Smallpox is a contagious, disfiguring and often deadly disease that has affected humans for thousands of years. Naturally occurring smallpox was eradicated worldwide by 1980, the result of an unprecedented global immunization campaign. Samples of smallpox virus have been kept for research purposes. This has led to concerns that smallpox could someday be used as a biological warfare agent. A vaccine can prevent smallpox, but the risk of the current vaccine’s side effects is too high to justify routine vaccination for people at low risk of exposure to the smallpox virus.

FORWARD-LOOKING STATEMENTS

This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA’s filings with the Securities and Exchange Commission, including SIGA’s Annual Report on Form 10-K for the year ended December 31, 2019, and in other documents that SIGA has filed with the SEC. SIGA urges investors and security holders to read those documents free of charge at the SEC’s web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements are current only as of the date on which such statements were made, and except for our ongoing obligations under the United States of America federal securities laws, we undertake no obligation to update publicly any forward-looking statements whether as a result of new information, future events, or otherwise.

The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.

Contacts:

Investors

David Carey
212-867-1768
[email protected]

Media

Stephanie Seiler
206-713-0124
[email protected]

______________________________________

1 http://www.mayoclinic.org/diseases-conditions/smallpox/basics/definition/con-20022769